CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation

The FDA released briefing materials on July 27, 2026, raising concerns about Capricor Therapeutics' deramiocel cell therapy for treating cardiomyopathy associated with Duchenne muscular dystrophy. The FDA's advisory panel voted 9-3 against the therapy, citing insufficient evidence of effectiveness and concerns that the company changed how it measured trial results. Following the announcement, Capricor's stock price plummeted approximately 67% on July 29, 2026, and fell another 50% in premarket trading on July 30, 2026.